Shares of American Renal Associates Holdings Inc (NYSE:ARA) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.89.
ARA has been the topic of a number of research analyst reports. Barclays set a $46.00 target price on shares of D. R. Horton and gave the company a “buy” rating in a research report on Friday, April 26th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.
American Renal Associates stock traded up $0.09 during mid-day trading on Thursday, reaching $6.84. The company had a trading volume of 7,775 shares, compared to its average volume of 217,196. American Renal Associates has a fifty-two week low of $5.48 and a fifty-two week high of $23.99. The firm has a market cap of $214.78 million, a P/E ratio of 10.71 and a beta of 1.93. The company has a fifty day moving average of $6.71.
Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in American Renal Associates by 47.5% during the fourth quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock worth $198,000 after buying an additional 5,549 shares during the last quarter. Bank of America Corp DE boosted its position in American Renal Associates by 6.2% in the fourth quarter. Bank of America Corp DE now owns 97,200 shares of the company’s stock valued at $1,120,000 after buying an additional 5,675 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in American Renal Associates by 21.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 33,900 shares of the company’s stock valued at $391,000 after buying an additional 5,925 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in American Renal Associates in the fourth quarter valued at approximately $125,000. Finally, Two Sigma Advisers LP boosted its position in American Renal Associates by 51.2% in the fourth quarter. Two Sigma Advisers LP now owns 45,500 shares of the company’s stock valued at $524,000 after buying an additional 15,400 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
See Also: Market Perform
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.